Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROMIST vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute coronary syndrome (off-label),Heart failure with preserved ejection fraction (off-label),Anal fissure (off-label)
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Primarily hepatic via glutathione S-transferases (GST) and possibly cytochrome P450 (CYP3A4) to inactive metabolites.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Approximately 60% bound to plasma proteins (albumin).
60% bound, primarily to plasma albumin
3.3 L/kg; large Vd indicates extensive tissue distribution, especially to vascular smooth muscle.
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Sublingual: ~40% (due to first-pass metabolism); transdermal: variable (~10–30%); intravenous: 100%.
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
No dose adjustment required for renal impairment.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction due to increased bioavailability.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Initiate with lower doses (e.g., 1 spray = 0.4 mg) due to increased sensitivity and higher risk of hypotension.
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
None.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension,Hypovolemia,Increased intracranial pressure,Hypertrophic cardiomyopathy,Severe anemia,Tolerance with continuous use,Contraindicated use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Hypersensitivity to nitroglycerin,Severe hypotension (SBP <90 mm Hg),Cardiac tamponade,Constrictive pericarditis,Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil),Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Severe anemia
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
Avoid alcohol consumption as it may enhance the hypotensive effects of nitroglycerin. No specific food restrictions, but a high-fat meal may delay absorption if taken orally; however, Nitromist is a sublingual spray, so food interactions are minimal.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: Increased risk of maternal hypotension leading to decreased placental perfusion. Not recommended.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio is approximately 0.55. American Academy of Pediatrics considers it compatible with breastfeeding. However, use caution in nursing mothers due to potential for infant hypotension.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
Standard dosing may be used but with caution due to increased plasma volume in pregnancy potentially altering pharmacokinetics. No specific dose adjustments recommended; start at lowest effective dose and titrate based on maternal response and fetal status.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
Nitromist (nitroglycerin lingual spray) is indicated for acute relief of angina pectoris. Onset of action is 1-3 minutes. Administer 1-2 sprays onto or under the tongue at the first sign of an attack; may repeat every 5 minutes up to 3 doses in 15 minutes. Do not shake canister. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Hypotension, reflex tachycardia, and headache are common. Tolerance may develop with frequent use; a nitrate-free interval of 10-12 hours can minimize tolerance.
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Use one or two sprays under or on the tongue at the first sign of chest pain; do not swallow. If no relief after 5 minutes, call 911.,Store at room temperature; do not expose to heat or open flame.,Do not shake the canister before use.,Sit down when using this medication to avoid dizziness or fainting.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra) while using this medication.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROMIST vs GONITRO, answered by our medical review team.
NITROMIST is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROMIST and GONITRO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROMIST is: 1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROMIST and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROMIST is classified as Category C. FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if cle. GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.